FMP

FMP

Enter

PCVX - Vaxcyte, Inc.

photo-url-https://images.financialmodelingprep.com/symbol/PCVX.png

Vaxcyte, Inc.

PCVX

NASDAQ

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

75.23 USD

0.86 (1.14%)

Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

34.03M

72.83M

46.83M

78.59M

47.07M

57.9M

71.22M

87.61M

107.76M

132.56M

Revenue %

-

114

-35.71

67.84

-40.11

23.01

23.01

23.01

23.01

Operating Cash Flow

88.13M

-128.95M

-153.09M

-102.83M

-194.5M

-34.74M

-42.73M

-52.57M

-64.66M

-79.53M

Operating Cash Flow %

258.95

-177.05

-326.92

-130.84

-413.2

-60

-60

-60

-60

Cap Ex

-9.1M

-1.6M

-2.84M

-34.48M

-12.84M

-12.29M

-15.12M

-18.59M

-22.87M

-28.13M

Cap Ex %

-26.73

-2.19

-6.06

-43.87

-27.27

-21.22

-21.22

-21.22

-21.22

Free Cash Flow

79.03M

-130.54M

-155.92M

-137.31M

-207.34M

-47.03M

-57.85M

-71.16M

-87.53M

-107.67M

Weighted Average Cost Of Capital

Price

34.49

Beta

Diluted Shares Outstanding

75.04M

Costof Debt

4.11

Tax Rate

After Tax Cost Of Debt

4.11

Risk Free Rate

Market Risk Premium

Cost Of Equity

Total Debt

87.76M

Total Equity

2.59B

Total Capital

2.68B

Debt Weighting

3.28

Equity Weighting

96.72

Wacc

14.27

Build Up Free Cash Flow

Year

2020

2021

2022

2023

2024

2025

2026

2027

2028

2029

Revenue

34.03M

72.83M

46.83M

78.59M

47.07M

57.9M

71.22M

87.61M

107.76M

132.56M

Operating Cash Flow

88.13M

-128.95M

-153.09M

-102.83M

-194.5M

-34.74M

-42.73M

-52.57M

-64.66M

-79.53M

Cap Ex

-9.1M

-1.6M

-2.84M

-34.48M

-12.84M

-12.29M

-15.12M

-18.59M

-22.87M

-28.13M

Free Cash Flow

79.03M

-130.54M

-155.92M

-137.31M

-207.34M

-47.03M

-57.85M

-71.16M

-87.53M

-107.67M

Wacc

14.27

14.27

14.27

14.27

14.27

Pv Lfcf

-41.16M

-44.3M

-47.68M

-51.33M

-55.25M

Sum Pv Lfcf

-239.72M

Terminal Value

Growth In Perpetuity Method

Long Term Growth Rate

Wacc

14.27

Free Cash Flow T1

-109.82M

Terminal Value

-894.7M

Present Terminal Value

-459.12M

Intrinsic Value

Enterprise Value

-698.84M

Net Debt

-32.49M

Equity Value

-666.35M

Diluted Shares Outstanding

75.04M

Equity Value Per Share

-8.88

Projected DCF

-8.88 4.884%

DCF Levered

Download Excel

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2024 © Financial Modeling Prep